Aim: To estimate current real-world costs of drugs and supportive care for the treatment of multiple myeloma in a tax-based health system. Methods: Forty-one patients were included from a personalized medicine study (2016-2019). Detailed information was collected from patient journals and hospital registries to estimate the total and mean costs using inverse probability weighting of censored data. Results: Total observed (censored) costs for the 41 patients was €8.84 million during 125 treatment years, with antineoplastic drugs as the main cost driver (€5.6 million). Individual costs showed large variations. Mean 3-year cost per patient from first progression was €182,103 (€131,800-232,405). Conclusion: Prediction of real-world costs is hindered by the availability of detailed costing data. Micro-costing analyses are needed for budgeting and real-world evaluation of cost-effectiveness.

TidsskriftFuture Oncology
Udgave nummer25
Sider (fra-til)3331-3341
Antal sider11
StatusUdgivet - sep. 2021


Dyk ned i forskningsemnerne om 'Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system'. Sammen danner de et unikt fingeraftryk.